Key Takeaways
- • ImmunityBio (IBRX) stock surged 12% to close at $8.83 on September 29, 2026, driven by institutional hedge fund validation and positive clinical/commercial developments; the stock has gained 256% over the past 12 months.
- • GA-Courtenay Special Situations Fund (Green Ash Partners) highlighted ImmunityBio as a top Q2 2026 holding, citing Anktiva's current addressable market of $5.8 billion annually based on one million vials per year at $35,000 per dose with 99% trailing gross margins.
- • Addressable market could expand beyond $43 billion annually if US lung cancer approval materializes by 2028, according to the fund's conservative pricing projections.
- • ImmunityBio secured a global partnership with Accord Healthcare to distribute Anktiva across 30 countries, expanding market access outside the United States.
- • A Phase 1b trial is underway testing N-803 combined with two additional cancer drugs in bladder cancer patients, representing a potential pipeline expansion catalyst.
Summary
ImmunityBio stock rose 12% on September 29, 2026, to $8.83 per share, extending a remarkable 256% gain over the past year as institutional investors increasingly focus on the biotech company's commercialization trajectory and clinical pipeline. The stock appreciation was catalyzed by GA-Courtenay Special Situations Fund, managed by Green Ash Partners, which named ImmunityBio a standout holding in its Q2 2026 investor letter, signaling confidence in the company's near-term and long-term growth potential.
The hedge fund's investment thesis centers on Anktiva, ImmunityBio's flagship immunotherapy drug, and the company's ability to scale production to meet market demand. GA-Courtenay highlighted ImmunityBio's manufacturing capacity of one million vials annually, with Anktiva priced at $35,000 per dose. Based on current approvals and manufacturing output, the fund estimates an addressable market exceeding $5.8 billion in annual revenue, supported by a 99% trailing gross margin—a metric that underscores the drug's profitability and production efficiency.
The fund's market expansion thesis hinges on regulatory approvals in additional indications. Anktiva already holds approval outside the US for lung cancer treatment, and the fund projects US approval could materialize by 2028. If approved, the addressable market could expand dramatically to beyond $43 billion annually, based on conservative pricing assumptions. This upside scenario represents substantial growth potential relative to current valuations and provides a clear catalyst timeline for institutional investors.
Recent commercial progress reinforces the investment narrative. ImmunityBio partnered with Accord Healthcare to expand Anktiva distribution across 30 countries, broadening geographic access and revenue opportunities. Concurrently, the company is advancing its clinical pipeline with a Phase 1b trial evaluating N-803 in combination with two additional cancer therapeutics in bladder cancer patients, positioning the company for potential label expansions that could unlock additional market segments and revenue streams.
The hedge fund's investment thesis centers on Anktiva, ImmunityBio's flagship immunotherapy drug, and the company's ability to scale production to meet market demand. GA-Courtenay highlighted ImmunityBio's manufacturing capacity of one million vials annually, with Anktiva priced at $35,000 per dose. Based on current approvals and manufacturing output, the fund estimates an addressable market exceeding $5.8 billion in annual revenue, supported by a 99% trailing gross margin—a metric that underscores the drug's profitability and production efficiency.
The fund's market expansion thesis hinges on regulatory approvals in additional indications. Anktiva already holds approval outside the US for lung cancer treatment, and the fund projects US approval could materialize by 2028. If approved, the addressable market could expand dramatically to beyond $43 billion annually, based on conservative pricing assumptions. This upside scenario represents substantial growth potential relative to current valuations and provides a clear catalyst timeline for institutional investors.
Recent commercial progress reinforces the investment narrative. ImmunityBio partnered with Accord Healthcare to expand Anktiva distribution across 30 countries, broadening geographic access and revenue opportunities. Concurrently, the company is advancing its clinical pipeline with a Phase 1b trial evaluating N-803 in combination with two additional cancer therapeutics in bladder cancer patients, positioning the company for potential label expansions that could unlock additional market segments and revenue streams.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.